Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit

Romualdo Barroso‐Sousa(Sociedade Brasileira de Oncologia Clínica), Sara M. Tolaney(Harvard University), Tess A. O’Meara(Yale University), Edward T. Richardson(Brigham and Women's Hospital), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Patrick A. Ott(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Zachary Weber(The Ohio State University), Nancy U. Lin(Dana-Farber Cancer Institute), Daniel G. Stover(Harvard University), Katharine A. Collier(The Ohio State University), Scott J. Rodig(Brigham and Women's Hospital), Deborah Dillon(Harvard University), Nikhil Wagle(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), Michael P. Manos(Harvard University), Katrina Kao(Dana-Farber Cancer Institute), Tejas Jammihal(Children's Hospital of Philadelphia), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Ofir Cohen(Broad Institute), F. Stephen Hodi(Harvard University), Victoria Attaya(Harvard University), Ryan Brennick(Dana-Farber Cancer Institute), Tanya E. Keenan(Massachusetts General Hospital), Juliet Forman(Broad Institute), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center)
JCO Precision Oncology
July 7, 2022
Cited by 41


Related Papers